SCHEMBL10324576

SCHEMBL10324576

c1cc(-c2n[nH]c3nc(NCCN4CCOCC4)ncc23)nc(NCc2ccsc2)n1

nearest known ligand 0.49

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ MKNK1 Q9BUB5 5/20 0.49
▸ DYRK1A Q13627 2/20 0.48
▸ DYRK1B Q9Y463 2/20 0.48
▸ EIF2AK2 P19525 3/20 0.46
▸ FLT3 P36888 4/20 0.45
▸ CXCR4 P61073 1/20 0.42
▸ CDK4 P11802 1/20 0.41
▸ GSK3B P49841 1/20 0.41
▸ HTR2A P28223 1/20 0.40
▸ LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10322363 0.89 CCNT1 (0.45) MKNK1DYRK1ADYRK1BEIF2AK2FLT3
SCHEMBL10323641 0.88 FLT3 (0.58) MKNK1DYRK1ADYRK1BEIF2AK2FLT3
SCHEMBL10323187 0.86 EIF2AK2 (0.53) MKNK1DYRK1ADYRK1BEIF2AK2FLT3
SCHEMBL10321614 0.86 DYRK1A (0.62) MKNK1DYRK1ADYRK1BEIF2AK2FLT3
SCHEMBL10324298 0.84 EGFR (0.41) MKNK1DYRK1ADYRK1BEIF2AK2HTR2A
SCHEMBL10322579 0.83 FLT3 (0.61) MKNK1DYRK1ADYRK1BEIF2AK2FLT3
SCHEMBL10323345 0.82 FLT3 (0.59) MKNK1DYRK1ADYRK1BEIF2AK2FLT3
SCHEMBL10322500 0.81 MKNK1 (0.50) MKNK1DYRK1ADYRK1BEIF2AK2FLT3
SCHEMBL10321912 0.80 MKNK1 (0.49) MKNK1DYRK1ADYRK1BEIF2AK2FLT3
SCHEMBL10323869 0.79 DYRK1A (0.46) MKNK1DYRK1ADYRK1BEIF2AK2FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362023-B2 Pyrazolo pyrimidines HOFFMANN-LA ROCHE INC. (US) 2013-01-29 — — US claimed
WO-2012098068-A1 PYRAZOLO PYRIMIDINES AS DYRK1A AND DYRK1B INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2012-07-26 — — WO claimed
US-20120184508-A1 PYRAZOLO PYRIMIDINES BIODURO (BEIJING) COMPANY LTD. (CN) 2012-07-19 — — US claimed
US-8362023-B2 Pyrazolo pyrimidines HOFFMANN-LA ROCHE INC. (US) 2013-01-29 — — US disclosed
US-8362023-B2 Pyrazolo pyrimidines HOFFMANN-LA ROCHE INC. (US) 2013-01-29 — — US disclosed
WO-2012098068-A1 PYRAZOLO PYRIMIDINES AS DYRK1A AND DYRK1B INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2012-07-26 — — WO disclosed
WO-2012098068-A1 PYRAZOLO PYRIMIDINES AS DYRK1A AND DYRK1B INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2012-07-26 — — WO disclosed
US-20120184508-A1 PYRAZOLO PYRIMIDINES BIODURO (BEIJING) COMPANY LTD. (CN) 2012-07-19 — — US disclosed
US-20120184508-A1 PYRAZOLO PYRIMIDINES BIODURO (BEIJING) COMPANY LTD. (CN) 2012-07-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184508-A1 PYRAZOLO PYRIMIDINES TYMS, TYMP, TP53 MKNK1 606/4885DYRK1A 1060/4885DYRK1B 1036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback